文献速递心力衰竭与心肌病

全球围产期心肌病女性临床表现、管理与6个月结局:ESC EORP注册研究

Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry.
PubMed 文献 · Eur Heart J · 2020-01-01

6个月死亡率为6%,心肌恢复(LVEF>50%)仅46%,临床表现与结局存在显著区域差异。

要点

  • PPCM患者诊断时67%有严重症状(NYHA III/IV),67% LVEF≤35%。
  • 6个月死亡率6%,心肌恢复率仅46%,区域差异显著。
  • 溴地平使用率15%,区域差异显著(P<0.001)。

核心结论

  • 围产期心肌病是全球性疾病,但临床表现和结局因区域而异。
  • 仅不到一半女性实现心肌恢复,孕产妇和新生儿发病率及死亡率显著。

研究设计与样本

  • 入选女性来自欧洲(33%)、非洲(29%)、亚太(15%)和中东(22%)。

主要发现

  • 平均年龄31±6岁,平均LVEF 31±10%,10%有既往妊娠并发PPCM。
  • 症状多在分娩后1个月内出现(44%),诊断时67%有严重症状(NYHA III/IV),67% LVEF≤35%。
  • 15%接受溴地平治疗,区域差异显著(欧洲15%,非洲26%,亚太8%,中东4%,P<0.001)。
  • 598例(81%)有随访,6个月总死亡率6%,欧洲最低(4%),中东最高(10%)。
  • 死亡多因心力衰竭(42%)或猝死(30%);再入院10%(其中过半因心衰),血栓栓塞事件7%;心肌恢复(LVEF>50%)仅46%,亚太最高(62%),中东最低(25%);新生儿死亡5%(欧洲2%,中东9%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We sought to describe the clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy (PPCM) globally. METHODS AND RESULTS: In 2011, >100 national and affiliated member cardiac societies of the European Society of Cardiology (ESC) were contacted to contribute to a global registry on PPCM, under the auspices of the ESC EURObservational Research Programme. These societies were tasked with identifying centres who could participate in this registry. In low-income countries, e.g. Mozambique or Burkina Faso, where there are no national societies due to a shortage of cardiologists, we identified potential participants through abstracts and publications and encouraged participation into the study. Seven hundred and thirty-nine women were enrolled in 49 countries in Europe (33%), Africa (29%), Asia-Pacific (15%), and the Middle East (22%). Mean age was 31 ± 6 years, mean left ventricular ejection fraction (LVEF) was 31 ± 10%, and 10% had a previous pregnancy complicated by PPCM. Symptom-onset occurred most often within 1 month of delivery (44%). At diagnosis, 67% of patients had severe (NYHA III/IV) symptoms and 67% had a LVEF ≤35%. Fifteen percent received bromocriptine with significant regional variation (Europe 15%, Africa 26%, Asia-Pacific 8%, the Middle East 4%, P < 0.001). Follow-up was available for 598 (81%) women. Six-month mortality was 6% overall, lowest in Europe (4%), and highest in the Middle East (10%). Most deaths were due to heart failure (42%) or sudden (30%). Re-admission for any reason occurred in 10% (with just over half of these for heart failure) and thromboembolic events in 7%. Myocardial recovery (LVEF > 50%) occurred only in 46%, most commonly in Asia-Pacific (62%), and least commonly in the Middle East (25%). Neonatal death occurred in 5% with marked regional variation (Europe 2%, the Middle East 9%). CONCLUSION: Peripartum cardiomyopathy is a global disease, but clinical presentation and outcomes vary by region. Just under half of women experience myocardial recovery. Peripartum cardiomyopathy is a disease with substantial maternal and neonatal morbidity and mortality.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sliwa K, Petrie MC, van der Meer P, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. 2020. PMID: 32840318. doi:10.1093/eurheartj/ehaa455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。